Portable neuroimaging development needs ethics guidance

By Published On: 13 September 2024
Portable neuroimaging development needs ethics guidance

A new study has found that ethical and legal guidance is not keeping up with the fast pace of development for highly accessible, portable neuroimaging.

The research team found that developers of portable neuroimaging have failed to formally address ethical, legal and social issues (ELSI) as they designed and deployed portable magnetic resonance imaging (MRI) systems.

The study was based on interviews with developers and scientists on the front lines of the portable brain scanner revolution, and covered a range of technologies: portable magnetoencephalography, electroencephalography, positron emission tomography, functional near-infrared spectroscopy, high-density diffuse optical tomography, and MRI.

Developers of these technologies were not aware of guidance for how to effectively address the ELSI challenges emerging in their work.

“It’s important to highlight the lack of specific ELSI guidance and engagement at the portable neuroimaging technology product development stage, where stakeholders have the opportunity to make choices that could prevent or address future harms or concerns specific to their imaging modality,” said co-author Frances Daniels of the University of Minnesota.

“Discussions with scientists and engineers made it clear that it’s easy to miss the societal implications of engineering decisions,” added co-author Efrain Torres.

“This work highlights the need for researchers, engineers and companies developing highly impactful technology to engage directly with the stakeholders they will one day impact.”

The study, carried out by the University of Minnesota, has been published in NMR in Biomedicine.

To address the gap, the authors recommend developers of these technologies work with ethics and legal experts to formulate guidelines. One base for such guidance could come from a recently-published article in the Journal of Law and the Biosciences.

How Lord Darzi's review could pave way for better spinal injury care
Luvadaxistat study fails to meet primary endpoint as schizophrenia treatment